IPP Bureau
Need for integration of various regulatory agencies : Pharma secretary
By IPP Bureau - March 26, 2021
Integration of various regulatory agencies with a single-window system and putting in place a transparent, stable, predictable and easy to navigate interface.
COVID-19 drug Remdesivir now priced at Rs. 899
By IPP Bureau - March 25, 2021
Zydus has made its brand of Remdesivir, Remdac more affordable at Rs. 899 for a 100 mg lyophilized injection.
LupinLife to promote hand hygiene at Kumbh Mela 2021
By IPP Bureau - March 24, 2021
Lupin will provide five lakh LupiSafe hand sanitizers to policemen and frontline workers deployed at strategic locations
NPPA brings 80 plus medicines under price regulation
By IPP Bureau - March 22, 2021
NPPA also fixed retail price of 76 new drugs in the meeting dated 10th March 2021 to be launched by existing manufacturers including off-patent Anti-diabetic drugs allowing due benefit of patent expiry to the patients.
Merck accelerates expansion plans for single-use products critical to manufacturing vaccines
By IPP Bureau - March 18, 2021
The company will add a single-use assembly production unit at its Life Science Center in Molsheim, France.
Merck brings new renewable energy to the grid through VPPA with Enel Green Power
By IPP Bureau - March 18, 2021
Has signed a 12-year, off-site, virtual power purchase agreement (VPPA) with Enel Green Power
LifeClean and Lonza Specialty Ingredients sign distribution agreement for disinfectants
By IPP Bureau - March 17, 2021
Lonza Specialty Ingredients has become LifeClean’s first strategic industrial partner.
Johnson & Johnson single-shot COVID-19 vaccine granted emergency use listing by WHO
By IPP Bureau - March 15, 2021
The vaccine was 85 percent effective in preventing severe disease across all regions.
AstraZeneca Pharma India receives approval for supplying Osimertinib in India
By IPP Bureau - March 13, 2021
The receipt of this permission paves way for the launch of Osimertinib 40mg/80mg film coated tablets in India.
Lupin launches authorized generic version of Alinia
By IPP Bureau - March 13, 2021
Nitazoxanide Tablets, 500 mg (RLD: Alinia) had estimated annual sales of USD 56 million in the U.S.
Govt. receives 215 applications for the 36 products under PLI scheme
By IPP Bureau - March 13, 2021
174 applications were received for 23 eligible products under Target Segment IV - Other Chemical Synthesis Based KSMs/ Drug Intermediates/APIs.
Altimmune expands AdCOVID manufacturing collaboration with Lonza
By IPP Bureau - March 13, 2021
AdCOVID is a COVID-19 vaccine candidate that is administered via nasal spray.
UPM Biomedicals and CELLINK collaborates for 3D bioprinting developments
By IPP Bureau - March 11, 2021
The collaboration of two strong partners, CELLINK and UPM, builds confidence in making these treatments into an industrial and clinical standard, applied in a wider setting instead of remaining only within few hospitals.
Lupin Pharma Canada announces Partnership with Endoceutics
By IPP Bureau - March 09, 2021
Intrarosa will not only expand and strengthen our product portfolio into Women's Health in Canada but will cater to satisfy the unmet medical needs.
NATCO receives approval for Everolimus tablets for the US market
By IPP Bureau - March 09, 2021
NATCO's partner BPI plans to launch 2.5 mg, 5 mg and 7.5 mg strengths of the product shortly within the next few weeks.
